Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Melanotan-II Ɔvaviu fɔ di wok
Melanotan-II (MT-II) na sεntetik α-melanosayt-stimulεt כmon (α-MSH) analכg we de insay di klas fכ melanocortin agonist dεm. MT-II nɔto fɔ jɔs tin dɛn we gɛt fɔ du wit tan; insay di fild fכ mεdikal risεch, dεn de εksplכr am fכ pכtεnshal aplikεshכn dεm fכ trit kכndishכn dεm lεk εrectile dysfunction.
Figure 1 Di strכkchכ fכ Melanotan-II.
Melanotan-II Mekanism fɔ Akshɔn
MT-II de fכs fכ du in ifekt dεm bay we i de intarakt wit melanocortin rεsεpכta dεm (MCR dεm). di melanocortin risεptor famili inklud mכltipכl sכbtayp dεm lεk MC1R, MC2R, MC3R, MC4R, εn MC5R. MT-II na nכn-sεlektiv mεlanokכtin rεsεptכr agonist we kin biεn εn aktibכt mכltipכl MCR dεm.
insay di skin, MT-II de biεn MC1R na di sεf fכ di melanosayt dεm, we de aktibכt adenylate cyclase, we de inkrεs di saykli AMP (cAMP) lεvεl, we de aktibכt protin kinaz A (PKA). PKA de aktibכt di maykroftalmia-asכsiet transkripshכn fכktכ (MITF) tru fכsfכrayleshכn. MITF na wan ki transkripshכn fכktכ insay melanin sεntez, I de upregulate di εksprεshכn fכ jin dεm lεk tayrosinase, tayrosinase-rεlatεd protin-1 (TRP-1), εn tayrosinase-rεlatεd protin-2 (TRP-2), we na εnzym dεm we de involv insay melanin sεntez, we kin lid to inkrεs pan di skin pigmεntεshכn εn achy wan tanning ifekt.
insay di nεv sistεm, MT-II de infכlכp sכm nyuroεndokrin sistεm dεm bak. i kin mek di sεntri כksijεn sistεm wok. stכdi dεn sho se intravenכs injεkshכn fכ MT-II de sכmtεm indyuz di εksprεshכn fכ Fos insay big nyuron dεm na di suprachiasmatic nyuklios (SON) εn paraventricular nyuklios (PVN) na di haypothalamus, wan rispכns we kin atεnuet bay prεviכs intrasεribroventrikular injεkshכn fכ di melanocortin antagonist SHU-9119. ilektrofisiolכjik rεkכdin dεm sho se intravenכs injεkshכn fכ MT-II de inkrεs di fayrin frεkwεns fכ כksitosin nyuron dεm na di SON bכt i nכ de trigεr dεndritik כksitosin rilis insay di SON. fכ di stכdi dεm we bin de bifo we sho se dayrekt aplikεshכn fכ melanocortin agonist dεm de inhεbit supraoptik nyuklios (SON) כksitosin nyuron dεm, di ifekt dεm fכ intravenכs MT-II kin atכs pat pan di mεdiet indaykt, pכtεnshal tru aktibכt input dεm frכm di kכdal bren stεm, usay MT-II de inkrεs Fos εksprεshכn bak.
apat frכm dat, MT-II gεt sכm mεkanism dεm fכ akshכn pan enεji mεtabolism εn tεmכrεguleshכn. insay maws εkspεriεns, intrapεritoneal injεkshכn fכ MT-II de indyuz signifyant εn transiεnt haypomεtabolism/haypothεrmia. dis haypothεmik fεnomen de disappear insay Kit W-sh/W-sh mays dεm we nכ gεt mast sεl dεm, we de sho se mast sεl dεm implεnt fכ MT-II-indyus haypothεrmia. MT-II kin stimulate mast sεl dεm tru כl tu di MRGPRB2-dipεndεnt εn -indipεndεnt mεkanism dεm fכ rilis histamin, we de prodyuz haypothεmia via histamin H 1 rεsεpכta dεm, as di sεlektiv antagonist pyrilamine כ ablashכn fכ H 1 rεsεpכta dεm de sכmtεm attenuate dis haypothεmik ifekt.
Ifekt dɛn we Melanotan-II gɛt
Rol in Skin Pigmɛnt
wan pan di mכst notabl ifekt dεm fכ MT-II na fכ indyuz inkrεs pan di skin pigmεnt, dat na fכ achy wan tanning ifekt. Fidbak frɔm di wan dɛn we yuz am sho se klos to ɔl di patisipan dɛn we bin tray fɔ tan wit MT-II bin sho se dɛn skin dɔn dak. dis sho se MT-II gεt sכm digri fכ כtonomi fכ indyuz skin pigmεntεshכn, we nכ de fulכp dipεnd pan כltravayolet rεdyushכn fכ initiate di melanogenesis mashin.In sכm stכdi dεm, obsכbishכn frכm animal mכdel dεm εn in vitro sεl εkspεriεns dεn sho se MT-II de stimulat melanosayt dεm dεn wan, we de upregulate di εksprεshכn fכ εnzym dεm we riliyt to melanin sεntez, we de protεkt melanin prodakshכn εn dakning di kɔlɔ we di skin gɛt. Dis ifekt de gi wan pɔtɛnɛshɛl ɔltɛrnativ fɔ di wan dɛn we de luk fɔ brɔnz kɔmpleks we dɛn de wɔri bɔt UV-induced skin damej.
Ifekt pan Nyurobiheviɔr
in tεm dεm fכ nyurobihayvכral ifekt dεm, MT-II de sho mכlti fכs akshכn dεm. Insay stεdi dεm we yuz zibra fish as mכdel, dεn fכnshכn se ivin sכt tεm hεy-fεt (HF) it (we de las כnli lεk 1% pan di zεbra fish in layfspan, כ tri wiks) kin mek dεn mεmכri fכ rεkכgnishכn, εlevεt anxiety lεvεl, εn rεdכks di εksplכratory tεndens insay zεbra fish. MT-II kin rivεs dεn abnכmaliti dεm ya we di it we gεt hεy fεt de mek, we de mek di zεbra fish in rεkכgnishכn mεmכri, wɔri, εn εksplכratory bihayvya kam bak to di lεvεl dεm we fiba di nכmal it grup.
Insay ɔtizm-rilayt risach, we dɛn yuz wan maternal immune activation (MIA) maws mɔdel fɔ simul ɔtizm, man MIA mays dɛn de sho ɔtizm-layk kwaliti dɛn, lɛk impεriɔs sɔshal bihayvya indikɛtɔ, ridyus vokal kɔmyunikeshɔn, ɛn inkris ripit bihayvya. Afta sɛvin dez MT-II tritmɛnt, sɔshal bihayvya indikɛtɔ dɛn na man MIA mays dɛn impɔtant, we sɔshal bihayvya indikɛtɔ dɛn na C57 mays dɛn wit nɔmal bakgrɔn sho nɔ impɔtant chenj afta MT-II tritmɛnt. Dis sho se MT-II gɛt pɔtɛnɛshɛl tritmɛnt ifɛkt fɔ impɔtant ɔtizm-layk bihayvya dɛfisit, we de gi nyu dairekshɔn fɔ ɔtizm tritmɛnt risach.
Figure 2 Adult man MIA mays dεn sho inkrεs pan כksitosin rεsεptכr εksprεshכn na di antεriכr cingulate kכtεks.
Efεkt dεm pan εnεji mεtabolism εn tεmכrεgulεshכn
MT-II gεt sכm ifekt dεm bak pan εnεji mεtabolism εn tεmכrεguleshכn. In maws εkspεriεns, mays wit pituitary adenylate cyclase-activating peptide (PACAP) dεfisiεns bin administret MT-II via pεrifεral injεkshכn de fכ tri kכnsekyutiv wik dεm di tεm we kol adapteshכn de. di risalts sho se MT-II kin patli rεstכr di impεriכs tεmכjεnεsis kapasiti fכ di mays dεm. bay we dεn mεzj norepinephrine-induced mεtabolik rεt, dεn fכnshכn se di tεmכjεnik kapasiti fכ mays dεm we dεn trit wit MT-II bin patli rεstכr. apat frכm dat, MT-II tritmεnt kכrekt difεkt dεm na lipid yutilizeshכn כnda adrenergic stimulashכn, we sho se MT-II kin infכlכw tεmכjεnεsis in brawn adipos tisu bay we i de rεgεl simpatik nεv aktiviti, we de ple rol fכ mεnten εnεji mεtabolik bεlε.
MT-II kin indyuz haypothεmia insay mays bay we i de aktibכt mast sεl dεm εn rilis histamin. dis prכsεs de sho di rol we MT-II de ple fכ tεmprachכ rεguleshכn mεkanism dεm.
di ifekt dεm we kin apin pan di rεprכdaktiv sistεm
MT-II gεt pכtεnshal ifekt dεm bak pan di rεprכdaktiv sistεm. dεn stכdi am fכ di tritmεnt fכ erectile dysfunction, we riliyt to in stimulatory ifekt dεm pan di rεprכdaktiv sistεm.
Aplikeshɔn dɛn fɔ Melanotan-II
Aplikeshɔn dɛn na di biuti industri
Insay di biuti industri, dɛn kin yuz MT-II mɔ as tanin ɛjɛn. Wit di want we de gro fɔ gɛt wɛlbɔdi, brɔnz kɔmpleks ɛn kɔnsyus bɔt di pɔtnɛshɛl skin damej we tradishɔnal san ɛkspos (lɛk san bɔn ɛn inkris risk fɔ skin kansa), MT-II dɔn gɛt atɛnshɔn as prɔdak we dɛn se i de ajɔst tanning we nɔ de abop pan san ɛksplɔshɔn. Bɔt bikɔs di ɛjɛnshi dɛm we gɛt pawa lɛk FDA nɔ gri fɔ am ɛn i nɔ gɛt big big stɔdi bɔt sef ɛn ɛfifikɛshɔn, di we aw dɛn de yuz am na di biuti makit stil de na grey eria. Insay sɔm kɔntri ɛn rijyɔn dɛn, wan wan tɛm, pipul dɛn kin sɛl MT-II na di intanɛt we nɔ rayt fɔ mek dɛn kɔsmɛtik.
Aplikeshɔn dɛn fɔ Mɛdikal Risach
Insay di fild fɔ mɛdikal risach, di aplikeshɔn fɔ MT-II fɔs fɔs fɔ ɛksplɔrɔ in pɔtɛnɛshɛl tritmɛnt aplikeshɔn fɔ difrɛn sik dɛn. Insay di kɔntɛks fɔ nyurobihayvya dizayd, MT-II dɔn sho se i ebul fɔ impɔtant nyurobihayvya abnɔmaliti we dɛn kin mek bay we dɛn it bɔku fat na zibra fish ɛn ɔtizm-layk bihayvya dɛfisit na man MIA mays, we de gi nyu risach dairekshɔn fɔ di tritmɛnt fɔ di nyurolɔjik dizayd dɛn we gɛt fɔ du wit am.
insay stכdi dεm pan enεji mεtabolism εn tεmכrεgulεshכn-rεlatεd sik dεm, MT-II in salvεj ifekt pan tεmכjεnεsis in PACAP-dεficient mays dεm de sho se in pכtεnshal valyu fכ trit mεtabolik sik dεm lεk fכ fat. fכda invεstigeshכn insay di rεgεdyushכn mεkanism dεm fכ MT-II pan εnεji mεtabolism-rεlatεd signal path dεm kin lid to divεlכpmεnt fכ nכvel tεrapi ejen fכ mεtabolik dizכrd dεm. stכdi dεm pan di mεkanism dεm we de כndalayn MT-II-indyus haypothεmia kin dip wi כndastandin bak fכ di fysiolojikal prכsεs dεm fכ tεmכrεguleshכn, we de gi wan tiori fכwndεshכn fכ di tritmεnt fכ sik dεm we de aכsכsiayt wit tεmכrεgεlεshכn abnכmaliti dεm.
Insay di fild fɔ riprodaktiv sistɛm sik, risach bɔt aw fɔ yuz MT-II fɔ trit di erectile dysfunction, pan ɔl we i stil de na in fɔs stej, de gi nyu opshɔn fɔ trit man seksual dysfunction.
Dɔn
Melanotan-II, as sεntetik α-melanosayt-stimulεt כmon analכg, gεt mכltipכl bayolojikal fכnshכn dεm we involv skin pigmεnt, nyurobihayvכral prכsεs, εnεji mεtabolism, tεmכrεguleshכn, εn di rεprכdaktiv sistεm. we i kam pan di skin pigmεnt, i kin mek di skin dak, we de gi wan pכtεnshal rod fכ tan. Insay di fild fɔ mɛdikal risach, MT-II de sho brayt aplikeshɔn prɔspɛkt. Risach pan nyurobihayvya dizכrd, enεji mεtabolism εn tεmכrεgulεshכn-rεlatεd sik dεm, εn riprodaktiv sistεm dizכrd de gi nyu dairekshכn fכ di tritmεnt fכ dεn kכndyushכn dεm ya.
Sos dɛn we dɛn pul
[1] McKenzie N, Gɔnzalɛz N, Huang C, ɛn ɔda pipul dɛn. Posta prεzεntεshכnPS09 Yuz εkspiriεns dεm fכ Melanotan II injεkshכn fכ tan[J]. British J ɔ rnal ɔ f Dɛmat ɔ l ɔ ji, 2024,191(Saplimɛnt_1):i179-i180.DOI: 10.1093/bjd/ljae090.380.
[2] Wekwejt P, Wojda U, Kiryk A. Melanotan-II de rivεs mεmכri impεryans we dεn indyuz bay sכt tεm HF it[J]. Bayomedisin & Famakoterapi, 2023,165:115129.DOI:10.1016/j.biopha.2023.115129.
[3] Tomassi S, Dimmito M. P., Cai M, ɛn ɔda pipul dɛn. CLIPsing Melanotan-II fכ Diskכv Mכltipכl Fכnshכnal Sεlektiv hMCR Agonist dεm[J]. J ɔ rnal ov M ɛ d ɛ sinal K ɛ m ɛ st ɛ r, 2022,65(5):4007-4017.DOI: 10.1021/acs.jmedchem.1c01848.
[4] Gilhooley E, Daly S, McKenna D. Melanotan II Yuz Ɛkspiriɛns: Wan Kwalitatif Stɔdi fɔ Onlayn Diskushɔn Fɔm[J]. Dɛmatɔlɔji, 2021,237(6):995-999.DOI:10.1159/000514492.
[5] Pitas B, Hadimeri H, Wahlberg R, ɛn ɔda pipul dɛn. Melanotan II: wan poshubul kכz fכ rεnal infarkshכn: rivyu fכ di litεrachכ εn kes ripot[J]. Cen Kes Ripɔt, 2020, 9 (2): 159-161.DOI: 10.1007/s13730-020-00447-z.
[6] Paiva L, Sabatier N, Leng G, ɛn ɔda pipul dɛn. Efεkt כf Melanotan-II pan Bren Fos Imyunoreaktiviti εn Oksitosin Nyurכnal Aktiviti εn Sekreshכn in Rat[J]. J ɔ rnal ov Nyuroεndkrinoloji, 2017,29(2).DOI:10.1111/jne.12454.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
